Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$223 Mln
P/E Ratio
--
P/B Ratio
7.38
Industry P/E
--
Debt to Equity
6.88
ROE
-1.23 %
ROCE
-22.27 %
Div. Yield
0 %
Book Value
0.13
EPS
-0.25
CFO
$-913.04 Mln
EBITDA
$-1,083.79 Mln
Net Profit
$-1,255.35 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Gossamer Bio (GOSS)
| 5.94 | -25.13 | 3.04 | 35.30 | -52.25 | -40.99 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Gossamer Bio (GOSS)
| -0.91 | -57.93 | -80.81 | 16.96 | -38.13 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 58.42 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small... molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California. Read more
Co-Founder, CEO, President & Chairman
Mr. Faheem Hasnain
Co-Founder, CEO, President & Chairman
Mr. Faheem Hasnain
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Gossamer Bio Inc (GOSS) stood at $ 315 Mln as on 31-Dec-24
The share price of Gossamer Bio Inc (GOSS) is $0.96 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Gossamer Bio Inc (GOSS) has given a return of -52.25% in the last 3 years.
Gossamer Bio Inc (GOSS) has a market capitalisation of $ 223 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Gossamer Bio Inc (GOSS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Gossamer Bio Inc (GOSS) and enter the required number of quantities and click on buy to purchase the shares of Gossamer Bio Inc (GOSS).
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
The CEO & director of Mr. Faheem Hasnain. is Gossamer Bio Inc (GOSS), and CFO & Sr. VP is Mr. Faheem Hasnain.
There is no promoter pledging in Gossamer Bio Inc (GOSS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Gossamer Bio Inc. (GOSS) | Ratios |
|---|---|
|
Return on equity(%)
|
-122.54
|
|
Operating margin(%)
|
-38.46
|
|
Net Margin(%)
|
-49.28
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Gossamer Bio Inc (GOSS) was $0 Mln.
$-0.02
(
